新型 SSTR 靶向肽 [F]SiTATE 在脑膜瘤中的下一代 PET/CT 成像：初步临床经验。

Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [F]SiTATE.

机构信息

Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.

Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.

出版信息

Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3390-3399. doi: 10.1007/s00259-023-06315-z. Epub 2023 Jun 26.

DOI:10.1007/s00259-023-06315-z

PMID:37358620

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10541820/

Abstract

BACKGROUND

Somatostatin-receptor (SSTR)-targeted PET/CT provides important clinical information in addition to standard imaging in meningioma patients. [F]SiTATE is a novel, F-labeled SSTR-targeting peptide with superior imaging properties according to preliminary data. We provide the first [F]SiTATE PET/CT data of a large cohort of meningioma patients.

METHODS

Patients with known or suspected meningioma undergoing [F]SiTATE PET/CT were included. Uptake intensity (SUV) of meningiomas, non-meningioma lesions, and healthy organs were assessed using a 50% isocontour volume of interest (VOI) or a spherical VOI, respectively. Also, trans-osseous extension on PET/CT was assessed.

RESULTS

A total of 107 patients with 117 [F]SiTATE PET/CT scans were included. Overall, 231 meningioma lesions and 61 non-meningioma lesions (e.g., post-therapeutic changes) were analyzed. Physiological uptake was lowest in healthy brain tissue, followed by bone marrow, parotid, and pituitary (SUV 0.06 ± 0.04 vs. 1.4 ± 0.9 vs. 1.6 ± 1.0 vs. 9.8 ± 4.6; p < 0.001). Meningiomas showed significantly higher uptake than non-meningioma lesions (SUV 11.6 ± 10.6 vs. 4.0 ± 3.3, p < 0.001). Meningiomas showed significantly higher uptake than non-meningioma lesions (SUVmax 11.6±10.6 vs. 4.0±3.3, p<0.001). 93/231 (40.3%) meningiomas showed partial trans-osseous extension and 34/231 (14.7%) predominant intra-osseous extension. 59/231 (25.6%) meningioma lesions found on PET/CT had not been reported on previous standard imaging.

CONCLUSION

This is the first PET/CT study using an F-labeled SSTR-ligand in meningioma patients: [F]SiTATE provides extraordinary contrast in meningioma compared to healthy tissue and non-meningioma lesions, which leads to a high detection rate of so far unknown meningioma sites and osseous involvement. Having in mind the advantageous logistic features of F-labeled compared to Ga-labeled compounds (e.g., longer half-life and large-badge production), [F]SiTATE has the potential to foster a widespread use of SSTR-targeted imaging in neuro-oncology.

摘要

背景

生长抑素受体（SSTR）靶向 PET/CT 除了标准成像外，还可为脑膜瘤患者提供重要的临床信息。[F]SiTATE 是一种新型的 F 标记的 SSTR 靶向肽，根据初步数据显示具有优越的成像性能。我们提供了首例 [F]SiTATE PET/CT 对大量脑膜瘤患者的研究数据。

方法

纳入了已知或疑似脑膜瘤并进行 [F]SiTATE PET/CT 检查的患者。使用 50%等体积感兴趣区（VOI）或球形 VOI 分别评估脑膜瘤、非脑膜瘤病变和健康器官的摄取强度（SUV）。此外，还评估了 PET/CT 上的跨骨延伸情况。

结果

共纳入了 107 例患者的 117 例 [F]SiTATE PET/CT 扫描。总共分析了 231 个脑膜瘤病变和 61 个非脑膜瘤病变（例如，治疗后改变）。正常脑组织的生理摄取最低，其次是骨髓、腮腺和垂体（SUV0.06±0.04 比 1.4±0.9 比 1.6±1.0 比 9.8±4.6；p<0.001）。脑膜瘤的摄取明显高于非脑膜瘤病变（SUV11.6±10.6 比 4.0±3.3，p<0.001）。脑膜瘤的摄取明显高于非脑膜瘤病变（SUVmax11.6±10.6 比 4.0±3.3，p<0.001）。93/231（40.3%）个脑膜瘤显示部分跨骨延伸，34/231（14.7%）个脑膜瘤主要为骨内延伸。231 个脑膜瘤病变中有 59 个（25.6%）在 PET/CT 上发现，而在之前的标准成像中并未报告。

结论

这是首例在脑膜瘤患者中使用 F 标记的 SSTR 配体进行的 PET/CT 研究：[F]SiTATE 与健康组织和非脑膜瘤病变相比，为脑膜瘤提供了极好的对比，从而提高了对目前未知脑膜瘤部位和骨受累的检测率。考虑到与 Ga 标记化合物相比，F 标记的有利逻辑特征（例如，更长的半衰期和大标签产量），[F]SiTATE 有可能促进 SSTR 靶向成像在神经肿瘤学中的广泛应用。